← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,486개
ADCBiologicstaleBioNTech SEPhase 3

Pumitamig (Pumitamig)

Non-small Cell Lung Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 19상태 RECRUITING
ADCBiologicstaleRemeGen Co., Ltd.Phase 3

disitamab vedotin (Disitamab Vedotin, RC48, RC48-ADC（2.0mg/kg）)

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
임상시험 19상태 RECRUITING
CGTBiologicChongqing Precision Biotech Co.…Phase 1

Targeted CEA CAR-T (Targeted CEA CAR-T)

Advanced Lung Cancer · CEA

#CEA#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 19상태 RECRUITING
AntibodystaleRocheApproved

trastuzumab (Herceptin, Trastuzumab rezetecan)

HER2-positive Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Approved#항체#면역항체+3
임상시험 19상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 3

Volrustomig (Volrustomig)

Metastatic Non-small Cell Lung Cancer · Endometrial Cancer

#EndometrialCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 19상태 RECRUITING
AntibodyRochePreclinical

atezolizumab (Tecentriq, Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Preclinical#항체#면역항체+2
효능 ORR 88.7%임상시험 18상태 RECRUITING
ADCBiologicstaleSichuan Baili Pharmaceutical Co…Phase 3

BL-M07D1 (BL-M07D1)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 18상태 RECRUITING
AntibodystaleRochePhase 1

Bevacizumab-IRDye800CW (Bevacizumab-IRDye800CW)

Adenomatous Polyposis Coli · Esophageal Cancer

#EsophagealCancer#Antibody#Phase1#항체#면역항체+3
임상시험 18상태 ACTIVE
AntibodystaleNeovii BiotechPhase 2

Catumaxomab (Catumaxomab)

Gastric Cancer; Gastric Adenocarcinoma · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+3
임상시험 18상태 ACTIVE
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Ifinatamab deruxtecan (Ifinatamab deruxtecan)

Prostate Cancer; Prostatic Neoplasms · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 18상태 RECRUITING
ADCBiologicstaleFondazione per la Medicina Pers…Phase 3

Pralsetinib (Pralsetinib)

Breast Cancer; Gastrointestinal Cancer · Solid Tumor

#SolidTumor#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 53.8%임상시험 18상태 ACTIVE
ADCBiologicstaleAstraZenecaPhase 2

AZD5305 (Saruparib, Saruparib (AZD5305))

Ovarian Cancer; Lung Adenocarcinoma · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 18상태 RECRUITING
ADCBiologicstaleBioMed Valley Discoveries, IncPhase 2

Ulixertinib (Ulixertinib)

Metastatic Colorectal Cancer · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 2%임상시험 18상태 RECRUITING
AntibodystaleBristol-Myers SquibbPhase 2

Urelumab (Urelumab)

Pancreatic Cancer · Malignant Tumors

#MalignantTumors#Antibody#Phase2#항체#면역항체+3
효능 ORR 5%임상시험 18상태 RECRUITING
ADCBiologicstaleMabwell (Shanghai) Bioscience C…Phase 3

9MW2821 (9MW2821)

Locally Advanced or Metastatic Triple-negative Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 RECRUITING
ADCBiologicstaleDanish Breast Cancer Cooperativ…Phase 3

Abemaciclib with ET (Abemaciclib with ET)

Metastatic Breast Cancer; ER-positive Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 0%임상시험 17상태 DISCONTINUED
ADCBiologicstaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Tislelizumab)

Breast Cancer; Neoadjuvant Therapy · Breast Cancer

#BreastCancer#ADC#Approved#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 ACTIVE
ADCBiologicstaleGenentech, Inc.Phase 1

GDC-0941 (GDC-0941)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 17상태 ACTIVE
ADCBiologicstaleShanghai JMT-Bio Inc.Phase 2

KN026 (KN026)

HER2-positive Colorectal Cancer; HER2-positive Biliary Tract Cancer · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 17상태 RECRUITING
AntibodystaleAmgenPhase 2

Panitumumab + paclitaxel (Panitumumab + paclitaxel)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 77.3%임상시험 17상태 ACTIVE

17 / 75 페이지

← 이전다음 →